litlas
Log inCreate account

Paul Nathan

Active 1978–2025

104
Papers
26,658
Citations
68
h-index
102
i10-index

Citations

Citations per year for Paul Nathan1956: 1 citations1971: 1 citations1981: 1 citations1982: 3 citations1983: 1 citations1984: 3 citations1985: 4 citations1986: 2 citations1987: 1 citations1988: 1 citations1989: 3 citations1994: 2 citations1995: 1 citations1996: 1 citations1997: 1 citations1998: 1 citations1999: 1 citations2000: 3 citations2001: 2 citations2006: 2 citations2007: 4 citations2008: 4 citations2009: 4 citations2010: 18 citations2011: 32 citations2012: 54 citations2013: 197 citations2014: 263 citations2015: 359 citations2016: 345 citations2017: 422 citations2018: 380 citations2019: 1,096 citations2020: 1,140 citations2021: 1,078 citations2022: 927 citations2023: 794 citations2024: 1,312 citations2025: 645 citations2026: 26 citations1957–1970: no citations, so these years are not shown1972–1980: no citations, so these years are not shown1990–1993: no citations, so these years are not shown2002–2005: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,649 citing papers, 23.1% of this breakdownChina: 945 citing papers, 8.2% of this breakdownItaly: 804 citing papers, 7% of this breakdownUnited Kingdom: 795 citing papers, 6.9% of this breakdownGermany: 676 citing papers, 5.9% of this breakdownFrance: 656 citing papers, 5.7% of this breakdownAustralia: 488 citing papers, 4.3% of this breakdownNetherlands: 445 citing papers, 3.9% of this breakdownSpain: 395 citing papers, 3.4% of this breakdownCanada: 366 citing papers, 3.2% of this breakdownSwitzerland: 316 citing papers, 2.8% of this breakdownJapan: 270 citing papers, 2.4% of this breakdown
0%23.1%Other 23.2%

Institutions

Fields

  • Medicine60.3%
  • Biochemistry, Genetics and Molecular Biology31.6%
  • Immunology and Microbiology3.6%
  • Computer Science0.9%
  • Engineering0.7%
  • Chemistry0.7%
  • Other2.2%

Topics

  • Cancer Immunotherapy and Biomarkers9.8%
  • Melanoma and MAPK Pathways8.8%
  • Cutaneous Melanoma Detection and Management5.6%
  • Immunotherapy and Immune Responses4.5%
  • CAR-T cell therapy research4.4%
  • Renal cell carcinoma treatment4.1%
  • Other62.8%

Coauthors

All papers

Open in search
  1. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

    Authors: Paul Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean‐François Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Josep M. Piulats, Mohammed Milhem, April K.S. Salama, Brendan D. Curti, Lev Demidov, Lauris Gastaud, Cornelia Mauch, Melinda Yushak, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Sophie Piperno‐Neumann - New England Journal of Medicine 2021 cited by 878

  2. Cross-cohort gut microbiome associations with immune checkpoint inhibitor response in advanced melanoma

    Authors: Karla A. Lee, Andrew Maltez Thomas, Laura A. Bolte, Johannes R. Björk, Laura Kist de Ruijter, Federica Armanini, Francesco Asnicar, Aitor Blanco‐Míguez, Ruth Board, Neus Calbet‐Llopart, Lisa Derosa, Nathalie Dhomen, Kelly Brooks, Mark Harland, Mark Harries, Emily R. Leeming, Paul Lorigan, Paolo Manghi, Richard Marais, Julia Newton‐Bishop, Luigi Nezi, Federica Pinto, Míriam Potrony, Susana Puig, Patricio Serra-Bellver, Heather M. Shaw, Sabrina Tamburini, Sara Valpione, Amrita Vijay, Levi Waldron, Laurence Zitvogel, Moreno Zolfo, Elisabeth G.E. de Vries, Paul Nathan, Rudolf S.N. Fehrmann, Véronique Bataille, Geke A.P. Hospers, Tim D. Spector, Rinse K. Weersma, Nicola Segata - Nature Medicine 2022 cited by 429

  3. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma

    Authors: Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, Bogusława Karaszewska, Axel Hauschild, E. Levchenko, Vanna Chiarion‐Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Helen Gogas, Mario Mandalà, John B.A.G. Haanen, Célèste Lebbé, Andrzej Maćkiewicz, Piotr Rutkowski, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith T. Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Maurizio Voi, Dirk Schadendorf, Georgina V. Long - New England Journal of Medicine 2019 cited by 1,376

  4. Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

    Authors: Caroline Robert, Bogusława Karaszewska, Jacob Schachter, Piotr Rutkowski, Andrzej Maćkiewicz, D. Stroiakovski, M. Lichinitser, Reinhard Dummer, Florent Grange, Laurent Mortier, Vanna Chiarion‐Sileni, Kamil Drucis, Ivana Krajsová, Axel Hauschild, Paul Lorigan, Pascal Wolter, Georgina V. Long, Keith T. Flaherty, Paul Nathan, Antoni Ribas, Anne-Marie Martin, Peng Sun, Wendy Crist, Jeff Legos, Stephen D. Rubin, Shonda M Little, Dirk Schadendorf - New England Journal of Medicine 2014 cited by 2,655

  5. Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

    Authors: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymyr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, Michelle Casey, Danièle Ouellet, Anne‐Marie Martin, Ngocdiep T. Le, Kiran Patel, Keith T. Flaherty - New England Journal of Medicine 2014 cited by 1,871

  6. Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma

    Authors: Jessica C. Hassel, Sophie Piperno‐Neumann, Piotr Rutkowski, Jean‐François Baurain, Max Schlaak, Marcus O. Butler, Ryan J. Sullivan, Reinhard Dummer, John M. Kirkwood, Marlana Orloff, Joseph J. Sacco, Sebastian Ochsenreither, Anthony M. Joshua, Lauris Gastaud, Brendan D. Curti, Josep M. Piulats, April K.S. Salama, Alexander N. Shoushtari, Lev Demidov, Mohammed Milhem, Bartosz Chmielowski, Kevin B. Kim, Richard D. Carvajal, Omid Hamid, Laura Collins, Koustubh Ranade, Chris Holland, Constance R. Pfeiffer, Paul Nathan - New England Journal of Medicine 2023 cited by 261

  7. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma

    Authors: Keith T. Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, Reinhard Dummer, Uwe Trefzer, James Larkin, Jochen Utikal, Brigitte Dréno, Marta Nyakas, Mark R. Middleton, Jürgen C. Becker, Michelle Casey, Laurie Sherman, Frank Wu, Danièle Ouellet, Anne‐Marie Martin, Kiran Klaus Patel, Dirk Schadendorf - New England Journal of Medicine 2012 cited by 2,141

  8. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

    Authors: Robert J. Motzer, Brian I. Rini, David F. McDermott, Osvaldo Arén Frontera, Hans J. Hammers, Michael A. Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S. Tykodi, Philippe Barthélémy, Raya Leibowitz‐Amit, Elizabeth R. Plimack, Sjoukje F. Oosting, Bruce G. Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K. Choueiri, Frede Donskov, Marc‐Oliver Grimm, Howard Gurney, Daniel Y.C. Heng, Christian Kollmannsberger, Michael R. Harrison, Yoshihiko Tomita, Ignacio Durán, Viktor Grünwald, M. Brent McHenry, Sabeen Mekan, Nizar M. Tannir - The Lancet Oncology 2019 cited by 780

  9. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

    Authors: Georgina V. Long, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, James Larkin, Claus Garbe, Thomas Jouary, Axel Hauschild, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Célèste Lebbé, Mario Mandalà, Michael Millward, Ana Arance, Igor Bondarenko, John B.A.G. Haanen, Johan Hansson, Jochen Utikal, Virginia Ferraresi, Н. В. Коваленко, Peter Mohr, Volodymr Probachai, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Douglas J. DeMarini, Jhangir G Irani, S. Swann, Jeffrey J. Legos, Fan Jin, Bijoyesh Mookerjee, Keith T. Flaherty - The Lancet 2015 cited by 1,386

  10. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

    Authors: Richard D. Carvajal, Marcus O. Butler, Alexander N. Shoushtari, Jessica C. Hassel, Alexandra P. Ikeguchi, Leonel F. Hernandez‐Aya, Paul Nathan, Omid Hamid, Josep M. Piulats, Matthew J. Rioth, Douglas B. Johnson, Jason J. Luke, Enrique Espinosa, Serge Leyvraz, Laura Collins, Howard Goodall, Koustubh Ranade, Chris Holland, Shaad E. Abdullah, Joseph J. Sacco, Takami Sato - Nature Medicine 2022 cited by 152

  11. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022

    Authors: Claus Garbe, Teresa Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Nicole Basset‐Séguin, Lars Bastholt, Véronique Bataille, V. del Mármol, Brigitte Dréno, Maria Concetta Fargnoli, Ana‐Maria Forsea, Jean-Jacques Grob, Christoph Höller, Roland Kaufmann, Nicole W.J. Kelleners-Smeets, Aimilios Lallas, Célèste Lebbé, Bohdan Lytvynenko, Josep Malvehy, D. Moreno‐Ramírez, Paul Nathan, Giovanni Pellacani, Philippe Saïag, Alexander J. Stratigos, Alexander C. J. van Akkooi, Ricardo Vieira, Iris Zalaudek, Paul Lorigan - European Journal of Cancer 2022 cited by 321

  12. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

    Authors: James Larkin, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, Charles Lance Cowey, Michael Schenker, Jean‐Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Anna Maria Di Giacomo, Mark R. Middleton, Jose Lutzky, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew G. Hill, Leslie A. Fecher, Michael Millward, Paul Nathan, Nikhil I. Khushalani, Paola Queirolo, Corey Ritchings, Maurice Lobo, Margarita Askelson, Hao Tang, Sonia Dolfi, Paolo A. Ascierto, Jeffrey S. Weber - Clinical Cancer Research 2023 cited by 180

  13. Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma

    Authors: Johannes R. Björk, Laura A. Bolte, Andrew Maltez Thomas, Karla A. Lee, Niccolò Rossi, Thijs T. Wind, Lotte M. Smit, Federica Armanini, Francesco Asnicar, Aitor Blanco‐Míguez, Ruth Board, Neus Calbet‐Llopart, Lisa Derosa, Nathalie Dhomen, Kelly Brooks, Mark Harland, Mark Harries, Paul Lorigan, Paolo Manghi, Richard Marais, Julia Newton‐Bishop, Luigi Nezi, Federica Pinto, Míriam Potrony, Susana Puig, Patricio Serra-Bellver, Heather M. Shaw, Sabrina Tamburini, Sara Valpione, Levi Waldron, Laurence Zitvogel, Moreno Zolfo, Elisabeth G.E. de Vries, Paul Nathan, Rudolf S.N. Fehrmann, Tim D. Spector, Véronique Bataille, Nicola Segata, Geke A.P. Hospers, Rinse K. Weersma - Nature Medicine 2024 cited by 124

  14. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Authors: Robert J. Motzer, Thomas E. Hutson, David Cella, James A. Reeves, Robert D. Hawkins, Jun Guo, Paul Nathan, Michael Staehler, Paul de Souza, Jaime R. Merchan, Ekaterini Boleti, Kate Fife, Jie Jin, Robert J. Jones, Hirotsugu Uemura, Ugo De Giorgi, Ulrika Harmenberg, Jinwan Wang, Cora N. Sternberg, Keith C. Deen, Lauren McCann, Michelle D. Hackshaw, Rocco J. Crescenzo, Lini Pandite, Toni K. Choueiri - New England Journal of Medicine 2013 cited by 1,918

  15. European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022

    Authors: Claus Garbe, Teresa Amaral, Ketty Peris, Axel Hauschild, Petr Arenberger, Nicole Basset‐Séguin, Lars Bastholt, Véronique Bataille, V. del Mármol, Brigitte Dréno, Maria Concetta Fargnoli, Ana‐Maria Forsea, Jean‐Jacques Grob, Christoph Höeller, Roland Kaufmann, Nicole W.J. Kelleners-Smeets, Aimilios Lallas, Célèste Lebbé, Bodhan Lytvynenko, Josep Malvehy, D. Moreno‐Ramírez, Paul Nathan, Giovanni Pellacani, Philippe Saïag, Alexander J. Stratigos, Alexander C. J. van Akkooi, Ricardo Vieira, Iris Zalaudek, Paul Lorigan - European Journal of Cancer 2022 cited by 287

  16. European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma—update 2023

    Authors: Ketty Peris, Maria Concetta Fargnoli, Roland Kaufmann, Petr Arenberger, Lars Bastholt, N. Basset Seguin, Véronique Bataille, Liève Brochez, V. del Mármol, Reinhard Dummer, Ana-Marie Forsea, Caroline Gaudy‐Marqueste, Catherine Harwood, Axel Hauschild, Christoph Höller, Lidija Kandolf, Nicole W.J. Kellerners-Smeets, Aimilios Lallas, Ulrike Leiter, Josep Malvehy, Branka Marinović, Željko Mijušković, D. Moreno‐Ramírez, Eduardo Nagore, Paul Nathan, Alexander Stratigos, Eggert Stockfleth, Luca Tagliaferri, Myrto Trakatelli, Ricardo Vieira, Iris Zalaudek, Claus Garbe - European Journal of Cancer 2023 cited by 267

  17. Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

    Authors: Reinhard Dummer, Georgina V. Long, Caroline Robert, Hussein A. Tawbi, Keith T. Flaherty, Paolo A. Ascierto, Paul Nathan, Piotr Rutkowski, О. В. Леонов, Caroline Dutriaux, Mario Mandalà, Paul Lorigan, Pier Francesco Ferrucci, Jean‐Jacques Grob, Nicolás Meyer, Helen Gogas, Daniil Stroyakovskiy, Ana Arance, Jan C. Brase, Steve Green, T Haas, Aisha Masood, Eduard Gasal, Antoni Ribas, Dirk Schadendorf - 2022 cited by 146

  18. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

    Authors: G.V. Long, K.T. Flaherty, Daniil Stroyakovskiy, Helen Gogas, E. Levchenko, Filippo de Braud, J. Larkin, C. Garbe, T. Jouary, A. Hauschild, Vanna Chiarion‐Sileni, C. Lebbe, M. Mandalá, M. Millward, Ana Arance, Igor Bondarenko, J.B.A.G. Haanen, J. Hansson, Jochen Utikal, Virginia Ferraresi, P. Mohr, V. Probachai, Dirk Schadendorf, Paul Nathan, C. Robert, A. Ribas, M.A. Davies, S.R. Lane, J.J. Legos, B. Mookerjee, Jean‐Jacques Grob - Annals of Oncology 2017 cited by 652

  19. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma

    Authors: Laura A. Bolte, Karla A. Lee, Johannes R. Björk, Emily R. Leeming, Marjo Campmans‐Kuijpers, Jacco J. de Haan, Arnau Vich Vila, Andrew Maltez Thomas, Nicola Segata, Ruth Board, Mark Harries, Paul Lorigan, Elisabeth G.E. de Vries, Paul Nathan, Rudolf S.N. Fehrmann, Véronique Bataille, Tim D. Spector, Geke A.P. Hospers, Rinse K. Weersma - JAMA Oncology 2023 cited by 96

  20. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

    Authors: Ulrich Keilholz, P.A. Ascierto, Reinhard Dummer, Caroline Robert, Paul Lorigan, Alexander C. J. van Akkooi, Ana Arance, Christian U. Blank, V. Chiarion Sileni, Marco Donia, Mark B. Faries, Caroline Gaudy‐Marqueste, Helen Gogas, Jean‐Jacques Grob, Matthias Gückenberger, John B.A.G. Haanen, Andrew Hayes, Christoph Höeller, Célèste Lebbé, Iwona Ługowska, Mario Mandalà, Iván Márquez‐Rodas, Paul Nathan, Bart Neyns, Roger Olofsson Bagge, Susana Puig, Piotr Rutkowski, Bastian Schilling, Vernon K. Sondak, Hussein A. Tawbi, Alessandro Testori, Olivier Michielin - Annals of Oncology 2020 cited by 233

  21. The gut microbiome: what the oncologist ought to know

    Authors: Karla A. Lee, Marilan Luong, Heather Shaw, Paul Nathan, Véronique Bataille, Timothy D. Spector - British Journal of Cancer 2021 cited by 147

  22. Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)

    Authors: Richard D. Carvajal, Sophie Piperno‐Neumann, Ellen Kapiteijn, Paul B. Chapman, Stephen Jay Frank, Anthony M. Joshua, Josep M. Piulats, Pascal Wolter, Véronique Cocquyt, Bartosz Chmielowski, T.R. Jeffry Evans, Lauris Gastaud, Gerald P. Linette, Carola Berking, Jacob Schachter, Manuel Rodrigues, Alexander N. Shoushtari, Delyth Clemett, Dana Ghiorghiu, G Mariani, Shirley Spratt, Susan Lovick, Peter Barker, Elaine Kilgour, Zhongwu Lai, Gary K. Schwartz, Paul Nathan - Journal of Clinical Oncology 2018 cited by 275

  23. Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

    Authors: Antoni Ribas, Richard Kefford, Margaret Marshall, Cornelis J.A. Punt, John B.A.G. Haanen, Maribel Mármol, Claus Garbe, Helen Gogas, Jacob Schachter, Gerald P. Linette, Paul Lorigan, Kari Kendra, Michele Maio, Uwe Trefzer, Michael Smylie, Grant A. McArthur, Brigitte Dréno, Paul Nathan, Jacek Mackiewicz, John M. Kirkwood, Jesús Gómez-Navarro, Bo Huang, Dmitri Pavlov, Axel Hauschild - Journal of Clinical Oncology 2013 cited by 815

  24. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

    Authors: Mahrukh M. Syeda, Jennifer Wiggins, Broderick C. Corless, Georgina V. Long, Keith T. Flaherty, Dirk Schadendorf, Paul Nathan, Caroline Robert, Antoni Ribas, Michael A. Davies, Jean‐Jacques Grob, Eduard Gasal, Matthew Squires, Mahtab Marker, James E. Garrett, Jan C. Brase, David Polsky - The Lancet Oncology 2021 cited by 93